Apollomics Inc. оголошує, що генеральний директор Гуо-Лян Юй, доктор філософії, призначений головою правління BayHelix Group

Foster City, CA, and Hangzhou, China, Jan 4, 2022 – (ACN Newswire) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022.

"I am honored to be selected by my peers to help guide the BayHelix Group as it continues to foster biotech innovations and expand business opportunities within the broad life sciences ecosystem globally," said Dr. Yu. "For 20 years, the BayHelix group has been an instrumental connection between emerging Chinese companies and the rest of the world. As a dual U.S. and China biotechnology company focused on the development of innovative therapies for cancer treatment, Apollomics has been actively involved with BayHelix since our inception. I look forward to offering my expertise and insights, and working with my distinguished BayHelix board of directors and fellow members, to further our goals towards connecting biopharmaceutical companies around the world."

About BayHelix Group

The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members. The diverse membership base covers many of the world's top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.

Про Apollomics Inc.

Apollomics Inc. — це інноваційна біофармацевтична компанія, яка займається відкриттям і розробкою монотерапії та комбінованої терапії препаратами, спрямованими на пухлину, та імуноонкологічними засобами. Продуктовий портфель компанії має кілька програм на різних стадіях розробки, включаючи нові, гуманізовані моноклональні антитіла, які відновлюють імунну систему організму, щоб розпізнавати та вбивати ракові клітини, і цільову терапію проти неконтрольованого росту сигнальних шляхів. Apollomics має операційні підрозділи у Фостер-Сіті, Каліфорнія, США, Ханчжоу та Шанхаї, Китай. Для отримання додаткової інформації відвідайте www.apollomicsinc.com.

Контактна інформація:

Контакти інвестора:
Вілсон В. Чунг
Фінансовий директор
(650) 209-4436
wcheung@apollomicsinc.com

Зв'язок із ЗМІ США:
Ремі Бернарда
Корпоративні комунікації
(415) 203-6386
remy.bernarda@apollomicsinc.com

Контакт зі ЗМІ Китаю:
Міжнародна група фінансових комунікацій Porda Havas
Келлі Фунг
Головний менеджер
(852) 3150 6763
kelly.fung@pordahavas.com


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comApollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022. Джерело: https://www.acnnewswire.com/press-release/english/72203/